Journal Home > Volume 11 , Issue 4
Nano Research 2018, 11(4): 2248-2255 https://doi.org/10.1007/s12274-017-1845-3
Research Article | Issue | Published: 19 March 2018

Nontoxic engineered virus nanofibers as an efficient agent for the prevention and detection of fungal infection

Show Author's Information Yicun Wang2,  Hongxi Shi1,  Shuai Dong1,  Yan Li1,  Meng Wang3,  Yanyan Huai1,  Xintong Zhang1,  Xi Chen1,  Chuanbin Mao4,5,  Xiang Gao1( ),  Li Wang1( )
Key Laboratory of Molecular Epigenetics of MOE and Institute of Genetics & CytologyNortheast Normal UniversityChangchun130024China
Jilin Provincial Key Laboratory on Molecular and Chemical GeneticThe Second Hospital of Jilin UniversityChangchun130024China
Department of Respiratory MedicineHarbin Medical University Cancer HospitalHarbin150081China
School of Materials Science and EngineeringZhejiang UniversityHangzhou310027China
Department of Chemistry & BiochemistryStephenson Life Science Research CenterUniversity of OklahomaNorman73019-5300USA
Keywords:
nanofiber, diagnosis, vaccine, phage, Candida albicans
Cite this article:
Wang Y, Shi H, Dong S, et al. Nontoxic engineered virus nanofibers as an efficient agent for the prevention and detection of fungal infection. Nano Research, 2018, 11(4): 2248-2255. https://doi.org/10.1007/s12274-017-1845-3
Download citation
EndNote(RIS)
BibTeX

521

Views

9

Downloads

Citations

9

Crossref

N/A

WoS

8

Scopus

1

CSCD

Abstract Full text Electronic supplementary material About this article

Candida albicans (C. albicans) infection has a high mortality rate in immunocompromised patients. Owing to the inefficiency of the current diagnostic system and the absence of licensed vaccines against candidiasis, the prevention of C. albicans infection remains a challenge. C. albicans infection can be evaluated and prevented by the anti-secreted aspartyl proteinase 2 antibody (anti-Sap2 IgG) and Hsp90 antibody (anti-Hsp90 IgG). In this study, to explore a new agent for the improvement of the diagnosis and the prevention of C. albicans infection, an engineered fd bacteriophage, which is considered a human-safe virus nanofiber, was designed and prepared with two epitopes that could induce and capture anti-Sap2 IgG and anti-Hsp90 IgG. The dual-display phage was employed as a novel capture probe to develop a new enzyme-linked immunosorbent assay (ELISA) method, which significantly improved the detection rate compared with those of the ELISA in which recombinant protein Sap2 was used as coating antigen to capture the specific antibodies (rSap2-ELISA) and the ELISA in which recombinant protein Hsp90 was used as coating antigen to capture the specific antibodies (rHsp90-ELISA). In addition, the nanofibers acted as a potential vaccine to immunize mice, as well as recombinant proteins, more efficiently mediated humoral and cellular immune responses, decreased levels of C. albicans colonization, and increased the survival rates in C. albicans-infected mice. Therefore, the phage dual-display nanofiber has been shown to be a powerful bifunctional agent for protection against and sensitive detection of clinical infections, which has the potential to be widely used in the life sciences, clinical medicine, and environmental sciences.


menu
Abstract
Full text
Outline
Electronic supplementary material
About this article

Nontoxic engineered virus nanofibers as an efficient agent for the prevention and detection of fungal infection

Show Author's information Yicun Wang2, Hongxi Shi1, Shuai Dong1, Yan Li1, Meng Wang3, Yanyan Huai1, Xintong Zhang1, Xi Chen1, Chuanbin Mao4,5, Xiang Gao1( ), Li Wang1( )
Key Laboratory of Molecular Epigenetics of MOE and Institute of Genetics & CytologyNortheast Normal UniversityChangchun130024China
Jilin Provincial Key Laboratory on Molecular and Chemical GeneticThe Second Hospital of Jilin UniversityChangchun130024China
Department of Respiratory MedicineHarbin Medical University Cancer HospitalHarbin150081China
School of Materials Science and EngineeringZhejiang UniversityHangzhou310027China
Department of Chemistry & BiochemistryStephenson Life Science Research CenterUniversity of OklahomaNorman73019-5300USA

Abstract

Candida albicans (C. albicans) infection has a high mortality rate in immunocompromised patients. Owing to the inefficiency of the current diagnostic system and the absence of licensed vaccines against candidiasis, the prevention of C. albicans infection remains a challenge. C. albicans infection can be evaluated and prevented by the anti-secreted aspartyl proteinase 2 antibody (anti-Sap2 IgG) and Hsp90 antibody (anti-Hsp90 IgG). In this study, to explore a new agent for the improvement of the diagnosis and the prevention of C. albicans infection, an engineered fd bacteriophage, which is considered a human-safe virus nanofiber, was designed and prepared with two epitopes that could induce and capture anti-Sap2 IgG and anti-Hsp90 IgG. The dual-display phage was employed as a novel capture probe to develop a new enzyme-linked immunosorbent assay (ELISA) method, which significantly improved the detection rate compared with those of the ELISA in which recombinant protein Sap2 was used as coating antigen to capture the specific antibodies (rSap2-ELISA) and the ELISA in which recombinant protein Hsp90 was used as coating antigen to capture the specific antibodies (rHsp90-ELISA). In addition, the nanofibers acted as a potential vaccine to immunize mice, as well as recombinant proteins, more efficiently mediated humoral and cellular immune responses, decreased levels of C. albicans colonization, and increased the survival rates in C. albicans-infected mice. Therefore, the phage dual-display nanofiber has been shown to be a powerful bifunctional agent for protection against and sensitive detection of clinical infections, which has the potential to be widely used in the life sciences, clinical medicine, and environmental sciences.

Keywords: nanofiber, diagnosis, vaccine, phage, Candida albicans

References(31)

1

Pfaller, M. A.; Diekema, D. J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin. Microbiol. Rev. 2007, 20, 133–163.
DOI Google Scholar
2

Brown, G. D.; Denning, D. W.; Gow, N. A. R.; Levitz, S. M.; Netea, M. G.; White, T. C. Hidden killers: Human fungal infections. Sci. Transl. Med. 2012, 4, 165rv13.
DOI Google Scholar
3

Sims, C. R.; Ostrosky-Zeichner, L.; Rex, J. H. Invasive candidiasis in immunocompromised hospitalized patients. Arch. Med. Res. 2005, 36, 660–671.
DOI Google Scholar
4

Wisplinghoff, H.; Bischoff, T.; Tallent, S. M.; Seifert, H.; Wenzel, R. P.; Edmond, M. B. Nosocomial bloodstream infections in us hospitals: Analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 2004, 39, 309–317.
DOI Google Scholar
5

Pemán, J.; Zaragoza, R. Current diagnostic approaches to invasive candidiasis in critical care settings. Mycoses 2010, 53, 424–433.
DOI Google Scholar
6

Cassone, A.; Casadevall, A. Recent progress in vaccines against fungal diseases. Curr. Opin. Microbiol. 2012, 15, 427–433.
DOI Google Scholar
7

Nguyen, M. H.; Clancy, C. J. Biomarkers for diagnosis of candidal infections. Curr. Fungal Infect. Rep. 2012, 6, 56–62.
DOI Google Scholar
8

Morrison, C. J.; Hurst, S. F.; Reiss, E. Competitive binding inhibition enzyme-linked immunosorbent assay that uses the secreted aspartyl proteinase of Candida albicans as an antigenic marker for diagnosis of disseminated candidiasis. Clin. Vaccine Immunol. 2003, 10, 835–848.
DOI Google Scholar
9

Singh, S. D.; Robbins, N.; Zaas, A. K.; Schell, W. A.; Perfect, J. R.; Cowen, L. E. Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS Pathog. 2009, 5, e1000532.
DOI Google Scholar
10

Naglik, J. R.; Challacombe, S. J.; Hube, B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol. Mol. Biol. Rev. 2003, 67, 400–428.
DOI Google Scholar
11

Vilanova, M.; Teixeira, L.; Caramalho, Í.; Torrado, E.; Marques, A.; Madureira, P.; Ribeiro, A.; Ferreira, P.; Gama, M.; Demengeot, J. Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2. Immunology 2004, 111, 334–342.
DOI Google Scholar
12

Wang, Y. C.; Su, Q. P.; Dong, S.; Shi, H. X.; Gao, X.; Wang, L. Hybrid phage displaying slaqvkytsassi induces protection against Candida albicans challenge in BALB/c mice. Hum. Vacc. Immunother. 2014, 10, 1057–1063.
DOI Google Scholar
13

Yang, Q.; Wang, L.; Lu, D. N.; Gao, R. J.; Song, J. N.; Hua, P. Y.; Yuan, D. W. Prophylactic vaccination with phage-displayed epitope of C. albicans elicits protective immune responses against systemic candidiasis in C57Bl/6 mice. Vaccine 2005, 23, 4088–4096.
DOI Google Scholar
14

Raska, M.; Belakova, J.; Raska, M.; Belakova, J.; Horynova, M.; Krupka, M.; Novotny, J.; Sebestova, M.; Weigl, E. Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis. Med. Mycol. 2008, 46, 411–420.
DOI Google Scholar
15

Gandra, N.; Abbineni, G.; Qu, X. W.; Huai, Y. Y.; Wang, L.; Mao, C. B. Bacteriophage bionanowire as a carrier for both cancer-targeting peptides and photosensitizers and its use in selective cancer cell killing by photodynamic therapy. Small 2013, 9, 215–221.
DOI Google Scholar
16

Mohan, K.; Weiss, G. A. Chemically modifying viruses for diverse applications. ACS Chem. Biol. 2016, 11, 1167–1179.
DOI Google Scholar
17

Suthiwangcharoen, N.; Li, T.; Li, K.; Thompson, P.; You, S. J.; Wang, Q. M13 bacteriophage-polymer nanoassemblies as drug delivery vehicles. Nano Res. 2011, 4, 483–493.
DOI Google Scholar
18

Wang, Y. C.; Ju, Z. G.; Cao, B. R.; Gao, X.; Zhu, Y.; Qiu, P. H.; Xu, H.; Pan, P. T.; Bao, H. Z.; Wang, L. et al. Ultrasensitive rapid detection of human serum antibody biomarkers by biomarker-capturing viral nanofibers. ACS Nano 2015, 9, 4475–4483.
DOI Google Scholar
19

Huovinen, T.; Syrjänpää, M.; Sanmark, H.; Seppä, T.; Akter, S.; Khan, L. M. F.; Lamminmäki, U. The selection performance of an antibody library displayed on filamentous phage coat proteins p9, p3 and truncated p3. BMC Res. Notes 2014, 7, 661.
DOI Google Scholar
20

Ghosh, D.; Kohli, A. G.; Moser, F.; Endy, D.; Belcher, A. M. Refactored m13 bacteriophage as a platform for tumor cell imaging and drug delivery. ACS Synth. Biol. 2012, 1, 576–582.
DOI Google Scholar
21

Løset, G. Å.; Bogen, B.; Sandlie, I. Expanding the versatility of phage display I: Efficient display of peptide-tags on protein vii of the filamentous phage. PLoS One 2011, 6, e14702.
DOI Google Scholar
22

Pan, P. T.; Wang, Y. C.; Zhu, Y.; Gao, X.; Ju, Z. G.; Qiu, P. H.; Wang, L.; Mao, C. B. Nontoxic virus nanofibers improve the detection sensitivity for the anti-p53 antibody, a biomarker in cancer patients. Nano Res. 2015, 8, 3562–3570.
DOI Google Scholar
23

Huai, Y. Y.; Dong, S.; Zhu, Y.; Li, X.; Cao, B. R.; Gao, X.; Yang, M. Y.; Wang, L.; Mao, C. B. Genetically engineered virus nanofibers as an efficient vaccine for preventing fungal infection. Adv. Healthc. Mater. 2016, 5, 786–794.
DOI Google Scholar
24

Pitarch, A.; Nombela, C.; Gil, C. Serum antibody signature directed against Candida albicans hsp90 and enolase detects invasive candidiasis in non-neutropenic patients. J. Proteome Res. 2014, 13, 5165–5184.
DOI Google Scholar
25

Ardizzoni, A.; Posteraro, B.; Baschieri, M.; Bugli, F.; Sáez-Rosòn, A.; Manca, L.; Cacaci, M.; Sterbini, F. P.; De Waure, C.; Sevilla, M. et al. An antibody reactivity-based assay for diagnosis of invasive candidiasis using protein array. Int. J. Immunopath. Pharmacol. 2014, 27, 403–412.
DOI Google Scholar
26

Qiu, M.; Zou, X. B.; Li, L. Preparation, purification and identification of polyclonal antibody against secretory aspartyl proteinase 2 of Candida albicans. Chin. J. Infect. Control 2013, 12, 241–246.
Google Scholar
27

Su, Q. P.; Huai, Y. Y.; Wang, Y. C.; Ju, Z. G.; Geng, Y. L.; Wang, L. The use of hybrid phage displaying antigen epitope and recombinant protein in the diagnosis of systemic Candida albicans infection in rabbits and cancer patients. Diagn. Microbiol. Infect. Dis. 2010, 68, 382–389.
DOI Google Scholar
28

Bazan, J.; Calkosinski, I.; Gamian, A. Phage display—A powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Hum. Vacc. Immunother. 2012, 8, 1817–1828.
DOI Google Scholar
29

Prisco, A.; De Berardinis, P. Filamentous bacteriophage Fd as an antigen delivery system in vaccination. Int. J. Mol. Sci. 2012, 13, 5179–5194.
DOI Google Scholar
30

Wang, G. Y.; Sun, M. Y.; Fang, J. B.; Yang, Q.; Tong, H. B.; Wang, L. Protective immune responses against systemic candidiasis mediated by phage-displayed specific epitope of Candida albicans heat shock protein 90 in C57BL/6J mice. Vaccine 2006, 24, 6065–6073.
DOI Google Scholar
31

Kashem, S. W.; Igyártó, B. Z.; Gerami-Nejad, M.; Kumamoto, Y.; Mohammed, J.; Jarrett, E.; Drummond, R. A.; Zurawski, S. M.; Zurawski, G.; Berman, J. et al. Candida albicans morphology and dendritic cell subsets determine T helper differentiation. Immunity 2015, 42, 356–366.
DOI Google Scholar
File
12274_2017_1845_MOESM1_ESM.pdf (1.2 MB)
Publication history
Copyright
Acknowledgements

Publication history

Received: 09 April 2017
Revised: 02 September 2017
Accepted: 06 September 2017
Published: 19 March 2018
Issue date: April 2018

Copyright

© Tsinghua University Press and Springer-Verlag GmbH Germany 2017

Acknowledgements

Acknowledgements

This work was supported by the National Natural Science Foundation of China (No. 81373231), the Department of Science and Technology of Jilin Province, China (No. 20160101216JC), the Programme for Introducing Talents to Universities (No. B07017), and Zhejiang Provincial Natural Science Foundation of China (No. LZ16E030001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Return